| CAS: | 65322-85-2 | ||
| 分子式: | C13H18O2 | ||
| 分子量: | 206.2808 | ||
| 沸点: | 327.445 °C | ||
| 中文名称: |
| ||
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||
| I906856 | MACKLIN | 3-(4-异丁基苯基)-丙酸 | 95% | 379元/1g; 1584元/5g; | 咨询 | ||||||||||||||||||||||||||||||||||||||
储存:室温,干燥 状态:白色到灰白色固体 | |||||||||||||||||||||||||||||||||||||||||||
| Y0000140 | Ibuprofen impurity F | European Pharmacopoeia (EP) Reference Standard | 1572.27元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. 包装 Unit quantity: 5 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||
| PHR1964 | Supelco | Ibuprofen impurity F | Pharmaceutical Secondary Standard; Certified Reference Material | 3006.31元/30 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Ibuprofen Impurity F is an impurity of the drug, ibuprofen. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that is effective against pain, inflammation and fever. It is deemed as a safe drug on account of its reversible inhibitory effects on cyclooxygenase (COX) enzyme along with its unique pharmacokinetics. 应用 These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements. 分析说明 These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 附注 To see an example of a Certificate of Analysis for this material enter LRAB2590 in the Documents slot below. This is an example certificate only and may not be the lot that you receive. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||
| 242532 | Fluorochem | 3-(4-Isobutylphenyl)propanoic acid | 97% | 1562元/1g; 5698元/5g; 20306元/25g; | 咨询 | ||||||||||||||||||||||||||||||||||||||
基本信息
安全信息
| |||||||||||||||||||||||||||||||||||||||||||
| HY-131259 | MCE | Ibuprofen Impurity F,65322-85-2_MCE(MedChemExpress) | 533元/10 mM * 1 mL in DMSO; 485元/1 g; 2040元/5 g; | 咨询 | |||||||||||||||||||||||||||||||||||||||
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。 Ibuprofen Impurity FMCE 国际站:Ibuprofen Impurity F 品牌:MedChemExpress (MCE) 货号:HY-131259 CAS 号:65322-85-2 生物活性:布洛芬杂质 F 是一种布洛芬杂质。布洛芬是一种抗炎抑制剂,靶向 COX-1 和 COX-2,其 IC50 分别为 13 μM 和 370 μM[1]。 分子量:206.28 Formula:C13H18O2 性状:固体 颜色:White to off-white 运输条件:美国大陆地区的室温;其他地区可能有所不同。 储存方式:粉末 -20°C 3年 提供质量检测报告:Data Sheet、SDS、COA、HNMR、RP-HPLC、产品使用指南 产品活性:Ibuprofen Impurity F 是 Ibuprofen 的杂质。Ibuprofen 是 COX-1 和 COX-2 的抑制剂,IC50 值分别为 13 μM 和 370 μM,具有抗炎的活性。 相关产品:Cisplatin | Y-27632 | PEG300 | PEG400 | PEG100000 | PEG1000000 | PEG200000 | PEG5000000 | PEG2000 | PEG8000000 | PEG3350 | PEG1500 热门产品线:抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products:Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向,为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择,助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献: 参考文献: 品牌介绍:
| |||||||||||||||||||||||||||||||||||||||||||